Subscribe to our Newsletters !!
The delicate, slend
Saint-Germain-en-Laye, France – October 5, 2021
Scientists have developed a chemical compound that
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Drug firm Alembic Pharmaceuticals on Monday said i
BioChromato report how their ionRocket sample prep
Mycelial cultures were obtained from fragments of
September 20, 2021 –– Takara Bio Europe AB (TBEAB) is proud to officially announce a partnership with the Boston IVF Fertility Center (Boston IVF) headquartered in Waltham, Massachusetts, USA. This partnership gives TBEAB access to discarded starting material for the derivation of clinical-grade hES cell lines for cell therapy research. “When we set off to establish our first clinical-grade hES cell line, we needed to find a partner that would accept the stringent donor and sourcing criteria”, said Kristina Runeberg, Site Head/Senior Director Corporate Development at TBEAB. “We were fortunate to find Boston IVF which has both the know-how and capabilities to fulfill the high regulatory demands required for this project. Through our initial collaboration, we were able to generate our first clinical-grade hES cell line which has recently been made available to cell therapy researchers through a new out-licensing program”.
This partnership also gives Boston IVF and the donor couples the opportunity to make compassionate use of surplus material that would otherwise be discarded. “While our main focus is on reproductive medicine and our world-renowned infertility treatment services, we also want to facilitate research that can help patients who are suffering from chronic or untreatable conditions,” said Denny Sakkas, CSO at Boston IVF. “We are excited to continue to work with TBEAB and help them to support innovative cell therapy researchers across the world.”
Learn more about TBEAB’s clinical-grade hES cell line derivation capabilities here. These services are also available in North America through Takara Bio USA, Inc.